摘要
CDC25(cell division cyclin 25)是调控细胞周期的重要蛋白,主要有CDC25A,CDC25B和CDC25C 3种亚型。CDC25B的过表达与许多癌症的发生有关,被认为是新的很有潜力的抗肿瘤药物靶点。高活性、高选择性的小分子抑制剂能为研究CDC25B在细胞通路中的生物功能和作用机制提供工具化合物,为抗肿瘤药物研究提供药物先导物。本文就2012年以来报道的CDC25B抑制剂做简要的综述。
Cell division cyclin 25（CDC25） is an important protein family regulating and controlling the cell cycle,including CDC25 A,CDC25B and CDC25 C. Overexpression of CDC25 B has been reported in numerous human tumors,and considered as a novel potential target of anticancer agents. The CDC25B-specific small molecule agents to modulate cellular processes through direct interaction with CDC25 B offer a number of attractive attributions to novel antitumor therapeutics. The recent development in the field of CDC25 B inhibitors since 2012 was briefly summarized in this review.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2014年第24期2881-2885,共5页
Chinese Journal of New Drugs
基金
中央高校基本科研业务费资助项目(JUSRP1040)
江苏省高等学校大学生实践创新训练计划(201310295035X)
关键词
CDC25B
抗肿瘤
抑制剂
构效关系
药物靶点
CDC25B
anticancer
inhibitors
structure activity relationship
drug target
